Latest research on Eszopiclone

Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic agent (viz., a sedative) used as a treatment for insomnia. Eszopiclone is the active stereoisomer of zopiclone, and belongs to the class of drugs known as cyclopyrrones. Its main selling point is that it is approved by the U.S. Food and Drug Administration for long-term use, unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia.

Latest findings

One can infer that the difference between Eszopiclone and placebo was only about 1 point on a small self-report scale which might confound sleep and mood. [source, 2007]
The on-line FDA NDA files for Zolpidem, Zaleplon, Eszopiclone, and ramelteon consist of hundreds of pages of reports, data, interpretations, and correspondence concerning each drug [8]. [source, 2007]
Notably, Krystal et al. reported a dropout rate of 2% due to depression in the Eszopiclone group (presumably 12 participants) and 0% in the placebo group (Chi Square = 3.9, P < 0.05, my computation). [source, 2007]
Fava and colleagues reported that symptoms of major depression were reduced when Eszopiclone was added to fluoxetine treatment. [source, 2007]
Considering reduction in Hamilton Depression Scores (with insomnia items removed) after 4 weeks, the effect of Eszopiclone was not significant, but after 8 weeks, the improvement in depression scores was 13% greater with Eszopiclone than with fluoxetine alone (p = 0.04). [source, 2007]
All CBs (14-gauge needle, Magnum® Core high speed, Bard Medica, Karlsruhe, Germany) were obtained under Sonographic guidance (HDI 5'000 Sono CT®, Philips, Zurich, Switzerland) under local anesthesia through a skin incision in a sterile field. [source, 2006]